Chronic daily administration of oral etoposide in refractory lymphoma

John D. Hainsworth, David H. Johnson, Sheryl R. Frazier, F. Anthony Greco

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41-77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.

Original languageEnglish (US)
Pages (from-to)818-821
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume26
Issue number7
DOIs
StatePublished - 1990

Fingerprint

Etoposide
Oral Administration
Lymphoma
Non-Hodgkin's Lymphoma
Alopecia
Leukopenia
Disease Progression
Appointments and Schedules
Leukocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chronic daily administration of oral etoposide in refractory lymphoma. / Hainsworth, John D.; Johnson, David H.; Frazier, Sheryl R.; Anthony Greco, F.

In: European Journal of Cancer and Clinical Oncology, Vol. 26, No. 7, 1990, p. 818-821.

Research output: Contribution to journalArticle

Hainsworth, John D. ; Johnson, David H. ; Frazier, Sheryl R. ; Anthony Greco, F. / Chronic daily administration of oral etoposide in refractory lymphoma. In: European Journal of Cancer and Clinical Oncology. 1990 ; Vol. 26, No. 7. pp. 818-821.
@article{45d55759c99b4a27b624094f02de3c30,
title = "Chronic daily administration of oral etoposide in refractory lymphoma",
abstract = "In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60{\%}) had partial responses (95{\%} CI 41-77{\%}), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28{\%}) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.",
author = "Hainsworth, {John D.} and Johnson, {David H.} and Frazier, {Sheryl R.} and {Anthony Greco}, F.",
year = "1990",
doi = "10.1016/0277-5379(90)90160-U",
language = "English (US)",
volume = "26",
pages = "818--821",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "7",

}

TY - JOUR

T1 - Chronic daily administration of oral etoposide in refractory lymphoma

AU - Hainsworth, John D.

AU - Johnson, David H.

AU - Frazier, Sheryl R.

AU - Anthony Greco, F.

PY - 1990

Y1 - 1990

N2 - In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41-77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.

AB - In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41-77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/μl during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.

UR - http://www.scopus.com/inward/record.url?scp=0025145356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025145356&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(90)90160-U

DO - 10.1016/0277-5379(90)90160-U

M3 - Article

C2 - 2145902

AN - SCOPUS:0025145356

VL - 26

SP - 818

EP - 821

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 7

ER -